Neurim Launches Second Bid to Pull Generic Version of its Insomnia Drug Off Market

shot by IP News Shots / 5:25 pm on 22 July, 2021

Neurim Pharmaceuticals has started a second round of litigation to take its generic version of insomnia medication off the market. The litigation has been initiated against two subsidiaries of Viatris Inc., despite the European Patent Office’s ruling last year that revoked the company’s parent patent. The High Court claim concerns a melatonin-based insomnia drug, a “divisional patent” of the parent patent.

Industry: Pharmaceuticals | Type of IP: Litigations

Read more at Law360